Video

Dr. Zhang on frontline treatment selection factors in metastatic kidney cancer

Author(s):

Urology Times staff

“We use a lot of clinical characteristics, but I’m hopeful we will start to go into more molecular typing and gene signatures,” says Tian Zhang, MD.

Tian Zhang, MD, associate professor at UT Southwestern Medical Center, discusses factors she uses in the clinic to decide among the evolving treatment options in the frontline setting for patients with metastatic renal cell carcinoma.

Related Videos
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Related Content
Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD
"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC
April 3rd 2025

Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC

Mehmet Asim Bilen, MD Hannah Clarke
"The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
April 2nd 2025

The importance of federal funding in cancer research: A call to action

Michael S. Cookson, MD, MMHC
"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
FDA updates in urology: March 2025
April 1st 2025

FDA updates in urology: March 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from March 2025.
Subcutaneous nivolumab under review in EU for solid tumors
March 31st 2025

Subcutaneous nivolumab under review in EU for solid tumors

Hannah Clarke
The European Commission must issue a decision on the application on or by June 2, 2025.
Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC
March 19th 2025

Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC

Hannah Clarke
"The positive results from this phase 3 study of the sintilimab and fruquintinib combination represent a significant advancement in the treatment of advanced renal cell carcinoma,” says Prof Zhisong He.
© 2025 MJH Life Sciences

All rights reserved.